Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report

M. D. DeFuria, R. B. Bracken, D. E. Johnson, M. S. Soloway, C. E. Merrin, L. R. Morgan, H. C. Miller, S. T. Crooke

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67% including a complete remission rate of 45%. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalCancer Treatment Reports
Volume64
Issue number2-3
StatePublished - Nov 18 1980
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Mitomycin
Urinary Bladder
Intravesical Administration
Poisons
Bone Marrow
Carcinoma
Therapeutics
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

DeFuria, M. D., Bracken, R. B., Johnson, D. E., Soloway, M. S., Merrin, C. E., Morgan, L. R., ... Crooke, S. T. (1980). Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report. Cancer Treatment Reports, 64(2-3), 225-230.

Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder : An interim report. / DeFuria, M. D.; Bracken, R. B.; Johnson, D. E.; Soloway, M. S.; Merrin, C. E.; Morgan, L. R.; Miller, H. C.; Crooke, S. T.

In: Cancer Treatment Reports, Vol. 64, No. 2-3, 18.11.1980, p. 225-230.

Research output: Contribution to journalArticle

DeFuria, MD, Bracken, RB, Johnson, DE, Soloway, MS, Merrin, CE, Morgan, LR, Miller, HC & Crooke, ST 1980, 'Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report', Cancer Treatment Reports, vol. 64, no. 2-3, pp. 225-230.
DeFuria MD, Bracken RB, Johnson DE, Soloway MS, Merrin CE, Morgan LR et al. Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report. Cancer Treatment Reports. 1980 Nov 18;64(2-3):225-230.
DeFuria, M. D. ; Bracken, R. B. ; Johnson, D. E. ; Soloway, M. S. ; Merrin, C. E. ; Morgan, L. R. ; Miller, H. C. ; Crooke, S. T. / Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder : An interim report. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 2-3. pp. 225-230.
@article{194c1cd1275947fab977bc59dfaa13d0,
title = "Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: An interim report",
abstract = "Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67{\%} including a complete remission rate of 45{\%}. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.",
author = "DeFuria, {M. D.} and Bracken, {R. B.} and Johnson, {D. E.} and Soloway, {M. S.} and Merrin, {C. E.} and Morgan, {L. R.} and Miller, {H. C.} and Crooke, {S. T.}",
year = "1980",
month = "11",
day = "18",
language = "English",
volume = "64",
pages = "225--230",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2-3",

}

TY - JOUR

T1 - Phase I-II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder

T2 - An interim report

AU - DeFuria, M. D.

AU - Bracken, R. B.

AU - Johnson, D. E.

AU - Soloway, M. S.

AU - Merrin, C. E.

AU - Morgan, L. R.

AU - Miller, H. C.

AU - Crooke, S. T.

PY - 1980/11/18

Y1 - 1980/11/18

N2 - Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67% including a complete remission rate of 45%. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.

AB - Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67% including a complete remission rate of 45%. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.

UR - http://www.scopus.com/inward/record.url?scp=0018829128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018829128&partnerID=8YFLogxK

M3 - Article

C2 - 7407754

AN - SCOPUS:0018829128

VL - 64

SP - 225

EP - 230

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2-3

ER -